Free Trial
LON:SCLP

Scancell (SCLP) Share Price, News & Analysis

Scancell logo
GBX 14 -0.50 (-3.45%)
(As of 11/22/2024 ET)

About Scancell Stock (LON:SCLP)

Key Stats

Today's Range
14
14.50
50-Day Range
12.78
16.70
52-Week Range
8.60
19.75
Volume
341,299 shs
Average Volume
681,083 shs
Market Capitalization
£130.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel immunotherapies and vaccines for the treatment of cancer and infectious disease. Its product candidates include SCIB1, an ImmunoBody cancer vaccine that is in Phase II for the treatment of metastatic melanoma; and SCIB2/iSCIB2 vaccine, which is under evaluation for the treatment of patients with solid tumors, including non-small cell lung cancer. It also develops Modi-1, a citrullinated peptides vaccine that is in phase I/II clinical trials for the treatment of solid tumors including triple negative breast, ovarian, renal, and head and neck cancers; and Modi-2, which targets homocitrullinated cancer antigens. In addition, the company focuses to develop SCOV1 and SCOV2 COVIDITY, a DNA vaccine against the SARS-CoV-2 virus. Scancell Holdings plc was founded in 1997 and is based in Oxford, the United Kingdom.

Receive SCLP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Scancell and its competitors with MarketBeat's FREE daily newsletter.

SCLP Stock News Headlines

Is Scancell the best penny stock for me to buy today?
“This Changes Everything” - Trump Hands Millions Massive IRS Gift
Now it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as we wait for Trump's agenda to kick in…
Scancell Holdings Moves Forward with Cancer Therapies
Scancell Holdings plc (SCNLF)
Scancell Holdings Share Chat (SCLP)
Scancell Holdings Announces Major Shareholding Changes
Scancell Appoints Phil L'Huillier As CEO
See More Headlines

SCLP Stock Analysis - Frequently Asked Questions

Scancell's stock was trading at GBX 10.50 on January 1st, 2024. Since then, SCLP stock has increased by 33.3% and is now trading at GBX 14.
View the best growth stocks for 2024 here
.

Scancell Holdings plc (LON:SCLP) announced its earnings results on Friday, January, 31st. The company reported ($0.56) EPS for the quarter.

Shares of SCLP stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Scancell investors own include KAZ Minerals (KAZ), Petropavlovsk (POG), Standard Chartered (STAN), AorTech International (AOR), Ascential (ASCL), Advanced Oncotherapy (AVO) and Empyrean Energy (EME).

Company Calendar

Last Earnings
1/31/2020
Today
11/23/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
51
Year Founded
N/A

Profitability

Net Income
£-5,860,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£5.27 million
Cash Flow
GBX 1.78 per share

Miscellaneous

Free Float
N/A
Market Cap
£130.14 million
Optionable
Not Optionable
Beta
0.35
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (LON:SCLP) was last updated on 11/24/2024 by MarketBeat.com Staff
From Our Partners